Molecular Genetic Approaches in the Therapy of Alzheimer’s Disease
Definitive treatment of Alzheimer’s disease (AD) will depend upon understanding the etiology and pathogenesis of this degenerative process. Techniques derived from studies of molecular genetics will identify individuals at high risk . These studies may also characterize the molecular defect(s) derived from the genetic expression of the disease, but we view them as future developments without clinical application for 1 to 2 decades. Alternatively, a shorter-term progress in the understanding of basic alterations of neurotransmitters, neuromodulators and growth factors may lead to the development of ameliorative or palliative therapies that attenuate the expression of symptoms and possibly even slow the disease process .
KeywordsNerve Growth Factor Alzheimer Disease Amyloid Protein Precursor Neuritic Plaque Amyloid Formation
Unable to display preview. Download preview PDF.
- 1.R.N. Rosenberg. Neurogenetics, Principles, and Practice. Raven Press, NY, Alzheimer’s disease, pp. 95–99 (1986).Google Scholar
- 2.E. Giacobini and R. Becker. 1988. Advances in therapy of Alzheimer’s disease. In: Familial Alzheimer’s Disease: Molecular Genetics, Clinical Perspectives, a Promising New Research. eds.G. Miner, J. Blass, R. Richter & J. Valentine. Marcel Dekker, Inc. New York (In press )Google Scholar
- 5.H.M. Wisniewski, G.S. Merz and R.I. Carp. Current hypothesis of the etiology and pathogenesis of senile dementia of the Alzheimer type. Interdiscipl. Topics Geront. 19, 45–53 (1985).Google Scholar
- 7.R.N. Rosenberg. Molecular genetics of Alzheimer’s disease; recent advances. Proceedings of the International Symposium on Alzheimer’s disease Abst., Kuopio, Finland (June, 1988 ).Google Scholar
- 8.D.A. Lewis, G.A. Higgins, W.G. Young, D. Goldgaber, D.C. Gajdusek, M.C. Wilson and J.H. Morrison. Distribution of precursor amyloid-0-protein messenger RNA in human cerebral cortex: Relationship to neurofibrillary tangles and neuritic plaques. Proc. Natl. Acad. Sci 85, 1691–1695 (1988).CrossRefGoogle Scholar
- 10.R.E. Tanzi, A.I. McClatchey, E.D. Lamperti, L. Villa-Komaroff, J.F. Gusella, R.L. Neve. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature, 528–530 (1988).Google Scholar
- 13.G. Bruce and G. Heinrich. The construction of human NGF expression vectors: Their potential role in the treatment of Alzheimer disease. 18th Annual Meeting Society for Neuroscience. Abst 331. 17 pp 827. (1988).Google Scholar
- 14.L. Olson, P. Enfors, T. Ebendal, P. Mouton, I. Stromberg and H. Persson. The establishment and use of stable cell lines that overexpress a transfected ß-NGF gene with studies in vitro, in oculo and intracranially. 18th Annual Meeting Society for Neuroscience Abst 276. 6 pp 684. (1988).Google Scholar